206 related articles for article (PubMed ID: 31981740)
21. HPV Meets APOBEC: New Players in Head and Neck Cancer.
Riva G; Albano C; Gugliesi F; Pasquero S; Pacheco SFC; Pecorari G; Landolfo S; Biolatti M; Dell'Oste V
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33573337
[TBL] [Abstract][Full Text] [Related]
22. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer.
Spanos WC; Nowicki P; Lee DW; Hoover A; Hostager B; Gupta A; Anderson ME; Lee JH
Arch Otolaryngol Head Neck Surg; 2009 Nov; 135(11):1137-46. PubMed ID: 19917928
[TBL] [Abstract][Full Text] [Related]
23. Uracil DNA glycosylase counteracts APOBEC3G-induced hypermutation of hepatitis B viral genomes: excision repair of covalently closed circular DNA.
Kitamura K; Wang Z; Chowdhury S; Simadu M; Koura M; Muramatsu M
PLoS Pathog; 2013; 9(5):e1003361. PubMed ID: 23696735
[TBL] [Abstract][Full Text] [Related]
24. Role of Host miRNA Hsa-miR-139-3p in HPV-16-Induced Carcinomas.
Sannigrahi MK; Sharma R; Singh V; Panda NK; Rattan V; Khullar M
Clin Cancer Res; 2017 Jul; 23(14):3884-3895. PubMed ID: 28143871
[No Abstract] [Full Text] [Related]
25. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.
Spreafico A; Huang SH; Xu W; Granata R; Liu CS; Waldron JN; Chen E; Ringash J; Bayley A; Chan KK; Hope AJ; Cho J; Razak AA; Hansen A; Jang R; Perez-Ordonez B; Weinreb I; Bossi P; Orlandi E; Licitra LF; Song Y; O'Sullivan B; Siu LL; Kim J
Eur J Cancer; 2016 Nov; 67():174-182. PubMed ID: 27669504
[TBL] [Abstract][Full Text] [Related]
26. Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts.
Kimple RJ; Harari PM; Torres AD; Yang RZ; Soriano BJ; Yu M; Armstrong EA; Blitzer GC; Smith MA; Lorenz LD; Lee D; Yang DT; McCulloch TM; Hartig GK; Lambert PF
Clin Cancer Res; 2013 Feb; 19(4):855-64. PubMed ID: 23251001
[TBL] [Abstract][Full Text] [Related]
27. Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring.
Paz IB; Cook N; Odom-Maryon T; Xie Y; Wilczynski SP
Cancer; 1997 Feb; 79(3):595-604. PubMed ID: 9028373
[TBL] [Abstract][Full Text] [Related]
28. Perturbation of base excision repair sensitizes breast cancer cells to APOBEC3 deaminase-mediated mutations.
Shen B; Chapman JH; Custance MF; Tricola GM; Jones CE; Furano AV
Elife; 2020 Jan; 9():. PubMed ID: 31904337
[TBL] [Abstract][Full Text] [Related]
29. Feasibility of quantitative PCR-based saliva rinse screening of HPV for head and neck cancer.
Zhao M; Rosenbaum E; Carvalho AL; Koch W; Jiang W; Sidransky D; Califano J
Int J Cancer; 2005 Nov; 117(4):605-10. PubMed ID: 15929076
[TBL] [Abstract][Full Text] [Related]
30. HPV and CSC in HNSCC cisplatin resistance.
Modur V; Thomas-Robbins K; Rao K
Front Biosci (Elite Ed); 2015 Jan; 7(1):58-66. PubMed ID: 25553363
[TBL] [Abstract][Full Text] [Related]
31. FDCSP Is an Immune-Associated Prognostic Biomarker in HPV-Positive Head and Neck Squamous Carcinoma.
Wu Q; Shao T; Huang G; Zheng Z; Jiang Y; Zeng W; Lv X
Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291667
[No Abstract] [Full Text] [Related]
32. Human Papillomavirus 16 E7 Stabilizes APOBEC3A Protein by Inhibiting Cullin 2-Dependent Protein Degradation.
Westrich JA; Warren CJ; Klausner MJ; Guo K; Liu CW; Santiago ML; Pyeon D
J Virol; 2018 Apr; 92(7):. PubMed ID: 29367246
[TBL] [Abstract][Full Text] [Related]
33. Dose-Modifying Factor of Radiation Therapy with Concurrent Cisplatin Treatment in HPV-Positive Squamous Cell Carcinoma: A Preclinical Study.
Prevc A; Kranjc S; Cemazar M; Todorovic V; Zegura B; Novak M; Filipic M; Flezar MS; Kirbis IS; Rotter A; Brozic A; Zakelj MN; Poljak M; Hosnjak L; Groselj B; Strojan P; Sersa G
Radiat Res; 2018 Jun; 189(6):644-651. PubMed ID: 29652621
[TBL] [Abstract][Full Text] [Related]
34. ATR inhibition sensitizes HPV
Leonard BC; Lee ED; Bhola NE; Li H; Sogaard KK; Bakkenist CJ; Grandis JR; Johnson DE
Oral Oncol; 2019 Aug; 95():35-42. PubMed ID: 31345392
[TBL] [Abstract][Full Text] [Related]
35. The HPV Induced Cancer Resource (THInCR): a Suite of Tools for Investigating HPV-Dependent Human Carcinogenesis.
Salnikov M; Gameiro SF; Zeng PYF; Barrett JW; Nichols AC; Mymryk JS
mSphere; 2022 Aug; 7(4):e0031722. PubMed ID: 35950764
[TBL] [Abstract][Full Text] [Related]
36. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
37. HPV Integration in Head and Neck Squamous Cell Carcinomas: Cause and Consequence.
Speel EJ
Recent Results Cancer Res; 2017; 206():57-72. PubMed ID: 27699529
[TBL] [Abstract][Full Text] [Related]
38. Concurrent weekly cisplatin and simultaneous integrated boost intensity-modulated radiotherapy of locally advanced squamous cell carcinoma of the head and neck.
Dubinský P; Jeremic B; Švajdová M; Barilíková G; Matula P; Nadzonová D; Vojtek V
Klin Onkol; 2022; 35(4):307-314. PubMed ID: 35989088
[TBL] [Abstract][Full Text] [Related]
39. Repair of APOBEC3G-Mutated Retroviral DNA
Salas-Briceno K; Ross SR
J Virol; 2021 Oct; 95(22):e0124421. PubMed ID: 34468176
[TBL] [Abstract][Full Text] [Related]
40. ΔNp63 activates the Fanconi anemia DNA repair pathway and limits the efficacy of cisplatin treatment in squamous cell carcinoma.
Bretz AC; Gittler MP; Charles JP; Gremke N; Eckhardt I; Mernberger M; Mandic R; Thomale J; Nist A; Wanzel M; Stiewe T
Nucleic Acids Res; 2016 Apr; 44(7):3204-18. PubMed ID: 26819410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
